share_log

Ardelyx | 8-K: Current report

Ardelyx | 8-K: Current report

Ardelyx | 8-K：重大事件
美股sec公告 ·  07/02 07:09
Moomoo AI 已提取核心信息
On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.
On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.
2024年7月2日，生物医药公司ardelyx宣布，决定不在CMS ESRD PPS TDAPA中纳入其药物XPHOZAH（tenapanor）。这个决定是为了维持患者对XPHOZAH的使用，XPHOZAH是一种磷吸收抑制剂，用于治疗晚期肾病患者。该公告在提交给SEC的8-K表格中发布。在纳斯达克全球市场上交易的ardelyx标的为ARDX，在此事项的影响或采取的任何其他策略方面，ardelyx未提供进一步的详情。
2024年7月2日，生物医药公司ardelyx宣布，决定不在CMS ESRD PPS TDAPA中纳入其药物XPHOZAH（tenapanor）。这个决定是为了维持患者对XPHOZAH的使用，XPHOZAH是一种磷吸收抑制剂，用于治疗晚期肾病患者。该公告在提交给SEC的8-K表格中发布。在纳斯达克全球市场上交易的ardelyx标的为ARDX，在此事项的影响或采取的任何其他策略方面，ardelyx未提供进一步的详情。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息